molecular formula Cl3Y B085317 Yttrium(III)-chlorid CAS No. 10361-92-9

Yttrium(III)-chlorid

Katalognummer: B085317
CAS-Nummer: 10361-92-9
Molekulargewicht: 195.26 g/mol
InChI-Schlüssel: PCMOZDDGXKIOLL-UHFFFAOYSA-K
Achtung: Nur für Forschungszwecke. Nicht für den menschlichen oder tierärztlichen Gebrauch.
Auf Lager
  • Klicken Sie auf QUICK INQUIRY, um ein Angebot von unserem Expertenteam zu erhalten.
  • Mit qualitativ hochwertigen Produkten zu einem WETTBEWERBSFÄHIGEN Preis können Sie sich mehr auf Ihre Forschung konzentrieren.

Beschreibung

Yttrium chloride is an inorganic compound composed of yttrium and chloride. It exists in two forms: the hydrate (YCl₃·6H₂O) and the anhydrous form (YCl₃). Both forms are colorless salts that are highly soluble in water and deliquescent . Yttrium chloride is used in various applications, including as a precursor for the synthesis of other yttrium compounds and in materials science.

Wirkmechanismus

Target of Action

Yttrium(III) chloride, also known as Yttrium chloride(III), is an inorganic compound of yttrium and chloride . It is used as a precursor to synthesize yttrium-based nanomaterials such as yttrium aluminum garnet nanopowder and organometallic yttrium complexes . These materials find application in the field of catalysis, electroluminescent devices, and superconductors . Therefore, the primary targets of Yttrium(III) chloride are these yttrium-based nanomaterials and their associated applications.

Mode of Action

Yttrium(III) chloride reacts with potassium alkoxotitanates to form precursors for titanium-containing ceramics . It is also used in the production of yttrium alkyl alkoxide complexes . The compound interacts with its targets through chemical reactions, leading to the formation of new compounds with desired properties.

Biochemical Pathways

It is known to be involved in the synthesis of yttrium-based nanomaterials and organometallic yttrium complexes , which can have various downstream effects depending on their specific applications.

Pharmacokinetics

It has been documented that most of the yttrium administered was distributed into liver, bone, and spleen . Yttrium disappeared from the blood within 1 day but was retained in the organs for a long time . These findings suggest that Yttrium(III) chloride may have low bioavailability due to its rapid clearance from the blood and long retention in the organs.

Result of Action

The molecular and cellular effects of Yttrium(III) chloride’s action largely depend on its application. For instance, when used as a precursor to synthesize yttrium-based nanomaterials, the result of its action is the formation of these nanomaterials with desired properties .

Action Environment

The action, efficacy, and stability of Yttrium(III) chloride can be influenced by various environmental factors. For example, its solubility in water and other solvents can affect its availability for reactions . Moreover, its reactivity with other substances can be influenced by factors such as temperature and pH.

Biochemische Analyse

Biochemical Properties

The biological effects of Yttrium refer to the activity, behavior, and toxicity of Yttrium element or compounds in cells, tissues, organs, and organisms . Yttrium is present in low abundance in soil, water bodies, and organisms . It is not an essential element for organisms and its bioavailability is very low .

Cellular Effects

Yttrium(III) chloride has been found to have acute hepatic injury and transient increase of plasma Ca following the injection . A significant and tremendous amount of Ca was deposited in the liver (over 10-fold) and spleen (over 100-fold), while Ca concentration was only slightly increased in the lung and kidney (less than 1.5-fold) . These results indicate that liver and spleen are primary target organs of intravenous-injected Yttrium(III) chloride .

Molecular Mechanism

Yttrium(III) chloride is taken up by phagocytic cells in the liver and spleen . Electron microscopic analyzes revealed that the colloidal yttrium-containing material was taken up by phagocytic cells in the liver and spleen .

Temporal Effects in Laboratory Settings

The elimination half-time of liver Y was 144 days at a dose of 1 mg Y/rat . Yttrium disappeared from the blood within 1 day but was retained in the organs for a long time .

Dosage Effects in Animal Models

The acute toxicity of Yttrium ion (Y3+), the deposition, retention, metabolism, and clearance have been documented in the previous reports . Hirano et al. studied time-course and dose-related changes in tissue distribution, subcellular localization, clearance, and acute toxicity of intravenous-injected Yttrium(III) chloride in rats .

Metabolic Pathways

Changes in Ca concentrations in liver, spleen, and lungs were in accordance with those of Yttrium(III) chloride . Two mechanisms of REE metabolism in the case of intravenous administration are suggested: (1) The REEs may be transported partly contained in serum protein and partly incorporated into phagocytes, and taken mostly into the reticuloendothelial system by the phagocytic mechanism and deposited there. (2) The major route of excretion of REEs may be biliary excretion and the REEs might be excreted gradually into feces .

Transport and Distribution

Yttrium(III) chloride is transported and distributed within cells and tissues . It is taken up by phagocytic cells in the liver and spleen .

Subcellular Localization

The subcellular localization of Yttrium(III) chloride is within the phagocytic cells in the liver and spleen . Electron microscopic analyzes revealed that the colloidal yttrium-containing material was taken up by phagocytic cells in the liver and spleen .

Vorbereitungsmethoden

Yttrium chloride is often prepared by the “ammonium chloride route,” starting from either yttrium oxide (Y₂O₃) or hydrated chloride or oxychloride . The synthetic route involves the following reactions:

    From Y₂O₃: [ 10 \text{NH}_4\text{Cl} + \text{Y}_2\text{O}_3 \rightarrow 2 (\text{NH}_4)_2[\text{YCl}_5] + 6 \text{NH}_3 + 3 \text{H}_2\text{O} ]

    From YCl₃·6H₂O: [ \text{YCl}_3·6\text{H}_2\text{O} + 2 \text{NH}_4\text{Cl} \rightarrow (\text{NH}_4)_2[\text{YCl}_5] + 6 \text{H}_2\text{O} ]

The pentachloride decomposes thermally to yield yttrium chloride(III): [ (\text{NH}_4)_2[\text{YCl}_5] \rightarrow 2 \text{NH}_4\text{Cl} + \text{YCl}_3 ]

Analyse Chemischer Reaktionen

Yttrium chloride undergoes various types of chemical reactions, including:

Common reagents and conditions used in these reactions include ammonium chloride, potassium alkoxotitanates, and high temperatures. Major products formed from these reactions include yttrium oxychloride and yttrium alkyl alkoxide complexes.

Vergleich Mit ähnlichen Verbindungen

Yttrium chloride can be compared with other similar compounds, such as:

  • Yttrium fluoride(III) (YF₃)
  • Yttrium bromide(III) (YBr₃)
  • Yttrium iodide(III) (YI₃)
  • Scandium chloride(III) (ScCl₃)
  • Lutetium chloride(III) (LuCl₃)

Yttrium chloride is unique due to its high solubility in water and its ability to form various yttrium-based materials. Its layered crystal structure, shared by compounds like aluminum chloride (AlCl₃), also contributes to its distinct properties .

Eigenschaften

CAS-Nummer

10361-92-9

Molekularformel

Cl3Y

Molekulargewicht

195.26 g/mol

IUPAC-Name

trichloroyttrium

InChI

InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3

InChI-Schlüssel

PCMOZDDGXKIOLL-UHFFFAOYSA-K

SMILES

[Cl-].[Cl-].[Cl-].[Y+3]

Kanonische SMILES

Cl[Y](Cl)Cl

10361-92-9

Physikalische Beschreibung

WetSolid

Verwandte CAS-Nummern

10025-94-2 (hexahydrate)

Synonyme

YCl3
yttrium chloride
yttrium chloride hexahydrate
yttrium chloride, (88)Y-labeled
yttrium chloride, (90)Y-labeled
yttrium chloride, (91)Y-labeled

Herkunft des Produkts

United States

Haftungsausschluss und Informationen zu In-Vitro-Forschungsprodukten

Bitte beachten Sie, dass alle Artikel und Produktinformationen, die auf BenchChem präsentiert werden, ausschließlich zu Informationszwecken bestimmt sind. Die auf BenchChem zum Kauf angebotenen Produkte sind speziell für In-vitro-Studien konzipiert, die außerhalb lebender Organismen durchgeführt werden. In-vitro-Studien, abgeleitet von dem lateinischen Begriff "in Glas", beinhalten Experimente, die in kontrollierten Laborumgebungen unter Verwendung von Zellen oder Geweben durchgeführt werden. Es ist wichtig zu beachten, dass diese Produkte nicht als Arzneimittel oder Medikamente eingestuft sind und keine Zulassung der FDA für die Vorbeugung, Behandlung oder Heilung von medizinischen Zuständen, Beschwerden oder Krankheiten erhalten haben. Wir müssen betonen, dass jede Form der körperlichen Einführung dieser Produkte in Menschen oder Tiere gesetzlich strikt untersagt ist. Es ist unerlässlich, sich an diese Richtlinien zu halten, um die Einhaltung rechtlicher und ethischer Standards in Forschung und Experiment zu gewährleisten.